Teva Fails On Quillivant XR Appeal – Five Years After Winning
Remanded 2020 District Court Decision Affirmed On Appeal
Executive Summary
Teva’s Actavis looks unlikely to be launching its proposed generic version of Tris Pharma’s Quillivant XR (methylphenidate) extended-release oral suspension soon, after a remanded district court decision that went against the firm was upheld on appeal.